Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel Free CSTL Stock Alerts

Castle Biosciences (CSTL) Competitors

Castle Biosciences logo
$35.19 +0.31 (+0.89%)
Closing price 04:00 PM Eastern
Extended Trading
$35.20 +0.01 (+0.03%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CSTL vs. CRVL, OPCH, AVAH, WGS, and PRVA

Should you buy Castle Biosciences stock or one of its competitors? Castle Biosciences's main competitors and comparable companies include CorVel (CRVL), Option Care Health (OPCH), Aveanna Healthcare (AVAH), GeneDx (WGS), and Privia Health Group (PRVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Castle Biosciences compare to CorVel?

CorVel (NASDAQ:CRVL) and Castle Biosciences (NASDAQ:CSTL) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

51.4% of CorVel shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 39.7% of CorVel shares are held by insiders. Comparatively, 6.1% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CorVel has a net margin of 11.72% compared to Castle Biosciences' net margin of -5.43%. CorVel's return on equity of 29.92% beat Castle Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
CorVel11.72% 29.92% 17.82%
Castle Biosciences -5.43%-4.15%-3.45%

CorVel has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

Castle Biosciences has a consensus price target of $42.00, suggesting a potential upside of 19.35%. Given Castle Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Castle Biosciences is more favorable than CorVel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CorVel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Castle Biosciences
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

CorVel has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CorVel$983.74M3.82$110.34M$2.2532.77
Castle Biosciences$357.28M3.01-$24.16M-$0.66N/A

In the previous week, Castle Biosciences had 1 more articles in the media than CorVel. MarketBeat recorded 8 mentions for Castle Biosciences and 7 mentions for CorVel. CorVel's average media sentiment score of 0.79 beat Castle Biosciences' score of -0.05 indicating that CorVel is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CorVel
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Castle Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

CorVel beats Castle Biosciences on 10 of the 17 factors compared between the two stocks.

How does Castle Biosciences compare to Option Care Health?

Castle Biosciences (NASDAQ:CSTL) and Option Care Health (NASDAQ:OPCH) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Castle Biosciences has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Option Care Health has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Option Care Health has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Option Care Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Castle Biosciences$357.28M3.01-$24.16M-$0.66N/A
Option Care Health$5.69B0.60$207.59M$1.3317.25

In the previous week, Castle Biosciences had 4 more articles in the media than Option Care Health. MarketBeat recorded 8 mentions for Castle Biosciences and 4 mentions for Option Care Health. Option Care Health's average media sentiment score of 0.55 beat Castle Biosciences' score of -0.05 indicating that Option Care Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Castle Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Option Care Health
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Castle Biosciences presently has a consensus target price of $42.00, indicating a potential upside of 19.35%. Option Care Health has a consensus target price of $29.92, indicating a potential upside of 30.44%. Given Option Care Health's higher probable upside, analysts plainly believe Option Care Health is more favorable than Castle Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Castle Biosciences
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80
Option Care Health
0 Sell rating(s)
7 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50

Option Care Health has a net margin of 3.68% compared to Castle Biosciences' net margin of -5.43%. Option Care Health's return on equity of 18.74% beat Castle Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Castle Biosciences-5.43% -4.15% -3.45%
Option Care Health 3.68%18.74%7.25%

92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 98.1% of Option Care Health shares are held by institutional investors. 6.1% of Castle Biosciences shares are held by insiders. Comparatively, 1.7% of Option Care Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Option Care Health beats Castle Biosciences on 10 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to Aveanna Healthcare?

Castle Biosciences (NASDAQ:CSTL) and Aveanna Healthcare (NASDAQ:AVAH) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Aveanna Healthcare has a net margin of 10.56% compared to Castle Biosciences' net margin of -5.43%. Aveanna Healthcare's return on equity of 80.70% beat Castle Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Castle Biosciences-5.43% -4.15% -3.45%
Aveanna Healthcare 10.56%80.70%7.42%

Aveanna Healthcare has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Aveanna Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Castle Biosciences$357.28M3.01-$24.16M-$0.66N/A
Aveanna Healthcare$2.60B1.04$225.03M$1.2310.07

Castle Biosciences has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, Aveanna Healthcare has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market.

In the previous week, Castle Biosciences had 4 more articles in the media than Aveanna Healthcare. MarketBeat recorded 8 mentions for Castle Biosciences and 4 mentions for Aveanna Healthcare. Aveanna Healthcare's average media sentiment score of 0.71 beat Castle Biosciences' score of -0.05 indicating that Aveanna Healthcare is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Castle Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aveanna Healthcare
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 88.0% of Aveanna Healthcare shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by company insiders. Comparatively, 5.3% of Aveanna Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Castle Biosciences currently has a consensus price target of $42.00, indicating a potential upside of 19.35%. Aveanna Healthcare has a consensus price target of $14.06, indicating a potential upside of 13.53%. Given Castle Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Castle Biosciences is more favorable than Aveanna Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Castle Biosciences
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80
Aveanna Healthcare
0 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.67

Summary

Aveanna Healthcare beats Castle Biosciences on 9 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to GeneDx?

Castle Biosciences (NASDAQ:CSTL) and GeneDx (NASDAQ:WGS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

GeneDx has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Castle Biosciences$357.28M3.01-$24.16M-$0.66N/A
GeneDx$454.43M5.81-$21.02M-$3.64N/A

Castle Biosciences has a net margin of -5.43% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat Castle Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Castle Biosciences-5.43% -4.15% -3.45%
GeneDx -23.41%4.12%2.26%

92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 6.1% of Castle Biosciences shares are held by insiders. Comparatively, 25.2% of GeneDx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Castle Biosciences currently has a consensus price target of $42.00, suggesting a potential upside of 19.35%. GeneDx has a consensus price target of $89.57, suggesting a potential upside of 1.23%. Given Castle Biosciences' higher probable upside, equities research analysts plainly believe Castle Biosciences is more favorable than GeneDx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Castle Biosciences
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80
GeneDx
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89

Castle Biosciences has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, GeneDx has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market.

In the previous week, GeneDx had 4 more articles in the media than Castle Biosciences. MarketBeat recorded 12 mentions for GeneDx and 8 mentions for Castle Biosciences. GeneDx's average media sentiment score of 0.52 beat Castle Biosciences' score of -0.05 indicating that GeneDx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Castle Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
GeneDx
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

GeneDx beats Castle Biosciences on 11 of the 15 factors compared between the two stocks.

How does Castle Biosciences compare to Privia Health Group?

Privia Health Group (NASDAQ:PRVA) and Castle Biosciences (NASDAQ:CSTL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

94.5% of Privia Health Group shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 5.7% of Privia Health Group shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Privia Health Group has a net margin of 1.19% compared to Castle Biosciences' net margin of -5.43%. Privia Health Group's return on equity of 3.52% beat Castle Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Privia Health Group1.19% 3.52% 2.00%
Castle Biosciences -5.43%-4.15%-3.45%

Privia Health Group currently has a consensus target price of $31.00, suggesting a potential upside of 59.88%. Castle Biosciences has a consensus target price of $42.00, suggesting a potential upside of 19.35%. Given Privia Health Group's higher probable upside, equities research analysts plainly believe Privia Health Group is more favorable than Castle Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Privia Health Group
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.79
Castle Biosciences
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

Privia Health Group has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Privia Health Group$2.36B1.05$22.92M$0.2192.33
Castle Biosciences$357.28M3.01-$24.16M-$0.66N/A

Privia Health Group has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

In the previous week, Castle Biosciences had 1 more articles in the media than Privia Health Group. MarketBeat recorded 8 mentions for Castle Biosciences and 7 mentions for Privia Health Group. Privia Health Group's average media sentiment score of 0.29 beat Castle Biosciences' score of -0.05 indicating that Privia Health Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Privia Health Group
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Castle Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Privia Health Group beats Castle Biosciences on 11 of the 17 factors compared between the two stocks.

Get Castle Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CSTL vs. The Competition

Export
MetricCastle BiosciencesHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.08B$9.65B$7.26B$13.10B
Dividend YieldN/A2.61%2.52%12.57%
P/E Ratio-53.3234.16274.9825.77
Price / Sales3.015.55679.2597.61
Price / Cash31.31122.1177.8052.76
Price / Book2.185.1910.526.34
Net Income-$24.16M$315.70M$3.49B$360.00M
7 Day Performance-4.32%-1.94%-1.08%-0.11%
1 Month Performance5.14%-2.33%-3.39%-3.42%
1 Year Performance55.23%12.96%15.08%5.46%

Castle Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CSTL
Castle Biosciences
2.0111 of 5 stars		$35.19
+0.9%		$42.00
+19.4%		+48.0%$1.08B$357.28MN/A1,002
CRVL
CorVel
1.5776 of 5 stars		$72.15
0.0%		N/A-8.5%$3.70B$983.74M32.225,239
OPCH
Option Care Health
3.6713 of 5 stars		$23.62
-1.6%		$29.92
+26.7%		-15.7%$3.54B$5.69B17.758,266
AVAH
Aveanna Healthcare
4.3988 of 5 stars		$14.12
-1.8%		$14.06
-0.4%		+52.4%$3.08B$2.60B11.4935,500
WGS
GeneDx
1.762 of 5 stars		$96.55
+7.6%		$89.57
-7.2%		-29.9%$2.89B$454.43MN/A1,300

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CSTL) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...
American Alternative | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...
Behind the Markets | Sponsoredtc pixel